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Aims The effects of vericiguat vs. placebo on high-sensitivity C-reactive protein (hsCRP) and serum uric acid (SUA) were
assessed in patients with heart failure with reduced ejection fraction (HFrEF) in the Phase 2 SOCRATES-REDUCED
study (NCT01951625).
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Methods
and results
Changes from baseline hsCRP and SUA values at 12 weeks with placebo and vericiguat (1.25 mg, 2.5 mg, 5.0 mg
and 10.0 mg, respectively) were assessed. The probability of achieving an hsCRP value of ≤3.0 mg/L or SUA value
of <7.0 mg/dL at week 12 was tested. Median baseline hsCRP and SUA levels were 3.68 mg/L [interquartile range
(IQR) 1.41–8.41; n= 335] and 7.80 mg/dL (IQR 6.40–9.33; n = 348), respectively. Baseline-adjusted mean percentage
changes in hsCRP were 0.2%, −19.5%, −24.3%, −25.7% and −31.9% in the placebo and vericiguat 1.25 mg, 2.5 mg,
5.0 mg and 10.0 mg groups, respectively; significance vs. placebo was observed in the vericiguat 10.0 mg group
(P = 0.035). Baseline-adjusted mean percentage changes in SUA were 5.0%, −1.3%, −1.1%, −3.5% and −5.3% in
the placebo, and vericiguat 1.25 mg, 2.5 mg, 5.0 mg and 10.0 mg groups, respectively; significance vs. placebo was
observed in the 5.0 mg and 10.0 mg groups (P = 0.0202 and P = 0.004, respectively). Estimated probability for an
end-of-treatment hsCRP value of ≤3.0 mg/L and SUA value of <7.0 mg/dL was higher with vericiguat compared with
placebo. The effect was dose-dependent, with the greatest effect observed in the 10.0 mg group.
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Conclusions Vericiguat treatment for 12 weeks was associated with reductions in hsCRP and SUA, and a higher likelihood of
achieving an hsCRP value of ≤3.0 mg/L and SUA value of <7.0 mg/dL.
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Keywords Heart failure • Ventricular ejection fraction • Biomarker • C-reactive protein • Uric acid •
Vericiguat
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Introduction
Inflammation and oxidative stress play key roles in the development
and progression of heart failure (HF).1,2 High-sensitivity C-reactive
protein (hsCRP) is an established marker of systemic inflamma-
tion and is associated with HF severity and outcomes.1,3–7 Uric
acid, the end product of purine metabolism, circulates at increased
serum levels in conditions of high oxidative stress and is fre-
quently elevated in patients with HF, in which it correlates with HF
severity and outcomes.6,8–10 Under conditions of oxidative stress,
endothelial dysfunction creates a deficiency in nitric oxide (NO)
and leads to impaired NO-soluble guanylate cyclase-cyclic guano-
sine monophosphate (NO-sGC-cGMP) signalling, and contributes,
amongst other pathways, to the development of HF.11,12
Vericiguat is a stimulator of sGC under investigation as a
first-in-class therapy for worsening chronic HF with reduced
ejection fraction (HFrEF).13 Although vericiguat did not meet
the primary endpoint [change from baseline in log-transformed
N-terminal pro-B-type natriuretic peptide (NT-proBNP) com-
pared with placebo at week 12] in the Phase 2 dose-finding
SOCRATES-REDUCED study (NCT01951625) in patients with
HFrEF, exploratory analyses suggested a dose–response asso-
ciation between higher vericiguat dose and greater reductions
in NT-proBNP compared with placebo.14 As vericiguat may
address inflammation and oxidative stress via its action on the
NO-sGC-cGMP pathway, we aimed to evaluate the effects of veri-
ciguat on hsCRP and serum uric acid (SUA) (markers of inflamma-
tion and oxidative stress) in patients with HFrEF using data from
the Phase 2 SOCRATES-REDUCED study.
Methods
Study design, treatment and assessments
SOCRATES-REDUCED (n = 456; protocol BAY 1021189/15371) was
a randomized, placebo-controlled, double-blind, dose-finding, Phase 2
study of vericiguat in patients with HFrEF.14 In brief, the study pop-
ulation comprised patients who were post-hospitalization for HF or
had received outpatient treatment with i.v. diuretics for HF. Patients
were eligible for inclusion in the SOCRATES-REDUCED study if they
had a left ventricular ejection fraction (LVEF) of <45% within 4 weeks
of a symptomatic HF event. Patients were randomized to 12 weeks of
treatment with vericiguat (1.25 mg, 2.5 mg, 5.0 mg and 10.0 mg once
daily) or placebo after clinical stabilization or within 4 weeks after dis-
charge. Dose up-titration (dose doubling) or sham titration occurred
at week 2 (visit 2) and week 4 (visit 3) after randomization, with dose
titration predicated on safety assessments and systolic blood pressure
criteria.15 The study design was published15 and is summarized in sup-
plementary material online Figure S1. The study conformed with the
principles outlined in the Declaration of Helsinki.16 Institutional review
board or ethics committee approval was obtained at each study site.
All patients provided written informed consent.
Blood samples were collected at all visits and centrifuged at 4∘C.
Serum and ethylenediaminetetraacetic acid plasma were aliquoted
and stored immediately at −20∘C or lower at study sites until they
were transported on dry ice to the central laboratory (Covance
Central Laboratory Services, Geneva, Switzerland), where samples



















































































.. High-sensitivity CRP was measured using an immunoturbidimetry
assay (Roche Diagnostics, Indianapolis, IN, USA). Assays for SUA
(Roche Diagnostics) were performed with the Roche Modular and
Cobas Analyzer. Baseline data were collected at visit 1, before ran-
domization and before the first intake of study treatment.
Other biomarkers investigated included bone alkaline phos-
phatase (bAP), cGMP, C-terminal telopeptide of type 1 collagen
(CTX), galectin-3 (Gal-3), growth differentiation factor 15 (GDF-15),
high-sensitivity troponin T (hsTnT), osteopontin (OPN), pro-collagen
III peptide (PIIINP), soluble suppression of tumorigenicity 2 (sST2) and
tissue metallopeptidase inhibitor 4 (TIMP-4).
Statistical analysis and model generation
The impacts of treatment in terms of biomarker changes from baseline
to end of treatment were evaluated with a linear mixed model
in order to account for intra-patient variability and differences in
biomarker baseline levels. All analyses were based on log-transformed
biomarker levels and the per-protocol population. Baseline-adjusted
mean hsCRP and SUA changes in each vericiguat treatment arm
were statistically compared with those in the placebo arm using
two-sided t-tests on the model contrasts. Dose dependency was
assessed by a linear trend test. The analyses for hsCRP and SUA were
performed with and without additional clinical covariates (age group,
sex, New York Heart Association functional class, diabetes and atrial
fibrillation).
Building on this analysis, risk cut-offs of hsCRP and SUA estab-
lished from prior studies were examined: hsCRP concentrations of
<1.0 mg/L, 1.0–3.0 mg/L and >3.0 mg/L, respectively, are associated
with low, moderate and high categories of relative risk for cardio-
vascular disease.17 Based on the linear mixed model, the expected
end of treatment value for a given baseline value and treatment was
calculated. The estimated probabilities of biomarker decreases to lev-
els below the risk cut-off (hsCRP ≤3.0 mg/L, SUA <7.0 mg/dL) dur-
ing the course of the study were calculated for all treatment groups
and selected baseline values within the observed range. These calcula-
tions were performed with consideration of the observed inter-patient
variability and on the assumption of a log-normal distribution of the
biomarkers.
The associations of hsCRP and SUA changes from baseline to end
of treatment with clinical outcomes (cardiovascular death, cardiovas-
cular hospitalization and emergency presentation caused by worsening
chronic HF) were assessed. The relative odds (odds ratio) of a clini-
cal outcome in each group (segmented by the direction of biomarker
change from baseline to end of treatment) were calculated and Fisher’s
exact test was conducted.
Results
Patients
The SOCRATES-REDUCED study was conducted across Europe,
North America and Asia between November 2013 and January
2015, with follow-up ending in June 2015. Randomized patients
with no major protocol deviations and biomarker values at baseline
and week 12 were included in the analysis (n = 328 and n = 345 in
the hsCRP and SUA analyses, respectively) (supplementary material
online Figure S2). Baseline characteristics for the full analysis set are
presented in supplementary material online Table S1.
© 2020 Bayer AG Pharmaceuticals. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 1 Baseline characteristics by high-sensitivity C-reactive protein subgroup







N = 328 (16.2%) (28.0%) (55.8%)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Age, years, median (IQR) 68.0 (58.0–76.0) 69.0 (60.0–78.0) 70.0 (60.8–79.2) 66.0 (57.0–74.5) 0.035
BMI, kg/m2, median (IQR) 27.6 (24.0–31.4) 26.5 (23.7–29.6) 27.1 (24.0–30.9) 28.2 (24.5–31.9) 0.041
Female sex, n 69 (21.0%) 15 (28.3%) 21 (22.8%) 33 (18.0%) 0.231
Non-White race, n 78 (23.8%) 15 (28.3%) 21 (22.8%) 42 (23.0%) 0.716
NYHA class III/IV, n 139 (42.4%) 16 (30.2%) 40 (43.5%) 83 (45.4%) 0.140
Atrial fibrillation, n 157 (47.9%) 29 (54.7%) 46 (50.0%) 82 (44.8%) 0.402
Arterial hypertension, n 254 (77.4%) 44 (83.0%) 65 (70.7%) 145 (79.2%) 0.163
Coronary artery disease, n 167 (50.9%) 25 (47.2%) 48 (52.2%) 94 (51.4%) 0.844
Chronic kidney disease, n 121 (36.9%) 20 (37.7%) 25 (27.2%) 76 (41.5%) 0.063
Diabetes mellitus, n 155 (47.3%) 21 (39.6%) 43 (46.7%) 91 (49.7%) 0.421
DBP, mmHg, median (IQR) 75.2 (69.6–81.7) 75.3 (69.0–79.7) 75.3 (68.3–82.0) 75.0 (70.0–83.0) 0.814
SBP, mmHg, median (IQR) 121.7 (115.6–134.4) 120.0 (114.7–128.7) 125.3 (117.0–135.5) 121.0 (115.0–136.5) 0.104
Heart rate, b.p.m., median (IQR) 70.5 (62.0–81.0) 69.3 (61.0–78.7) 71.0 (60.7–81.5) 70.7 (63.1–81.2) 0.655
LVEF, %, median (IQR) 29.2 (23.3–36.0) 29.8 (24.5–33.9) 31.2 (24.9–36.8) 28.5 (23.0–37.1) 0.350
Serum sodium, mmol/L, median (IQR) 139.0 (137.0–141.0) 139.0 (137.0–141.0) 139.5 (137.0–141.0) 139.0 (136.0–140.0) 0.194
Serum creatinine, mg/dL, median (IQR) 1.2 (1.0–1.4) 1.1 (1.0–1.3) 1.2 (1.0–1.4) 1.2 (1.0–1.5) 0.397
eGFR, mL/min/1.73 m2, median (IQR) 56.3 (44.4–72.6) 55.3 (47.9–64.6) 56.3 (41.3–75.0) 56.3 (44.5–73.8) 0.689
BMI, body mass index; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; hsCRP, high-sensitivity C-reactive protein; IQR, interquartile range; LVEF, left
ventricular ejection fraction; NYHA, New York Heart Association; SBP, systolic blood pressure.
aP-values are based on Fisher’s exact tests for sex, race, NYHA class, atrial fibrillation, arterial hypertension, coronary artery disease, chronic kidney disease and diabetes
mellitus, and on Kruskal–Wallis tests for other baseline characteristics.
Biomarker evaluation at baseline
Overall median hsCRP was 3.68 mg/L [interquartile range
(IQR) 1.41–8.41 mg/L] at baseline. Within each treatment
arm, baseline median hsCRP values were 3.98 mg/L (IQR
1.54–8.46 mg/L), 5.45 mg/L (IQR 1.78–10.75 mg/L), 3.62 mg/L
(IQR 1.29–7.58 mg/L), 3.88 mg/L (IQR 1.29–8.60 mg/L) and
2.81 mg/L (IQR 1.37–6.62 mg/L) in the placebo, and vericiguat
1.25 mg, 2.5 mg, 5.0 mg and 10.0 mg groups, respectively.
Median SUA was 7.80 mg/dL (IQR 6.40–9.33 mg/dL) at base-
line. Within each treatment arm, baseline median SUA val-
ues were 7.50 mg/dL (IQR 6.30–9.90 mg/dL), 7.40 mg/dL (IQR
6.10–8.70 mg/dL), 7.90 mg/dL (IQR 6.88–9.13 mg/dL), 8.25 mg/dL
(IQR 6.63–9.80 mg/dL) and 7.95 mg/dL (IQR 6.55–9.38 mg/dL) in
the placebo, and vericiguat 1.25 mg, 2.5 mg, 5.0 mg and 10.0 mg
groups, respectively.
Patient demographics by baseline hsCRP and SUA subgroups
are shown in Tables 1 and 2, respectively. There were several
differences between patients with lower and higher hsCRP and
SUA values at baseline: patients with higher hsCRP and SUA values
at baseline were of a slightly younger age and had a higher body
mass index; patients with higher SUA at baseline had a lower LVEF,
systolic blood pressure, serum sodium and estimated glomerular
filtration rate (eGFR), and a higher serum creatinine level.
Biomarker evaluation following
treatment
Baseline-adjusted mean hsCRP and SUA changes (%) from












































. groups are shown in Figure 1. Following 12 weeks of treatment,
baseline-adjusted mean percentage changes from baseline in hsCRP
were 0.2% [95% confidence interval (CI)] −22.4 to 29.3], −19.5%
(95% CI −37.8 to 4.1), −24.3% (95% CI −41.1 to −2.7), −25.7%
(95% CI −42.6 to −3.7) and −31.9% (95% CI −47.2 to −12.3) in
the placebo, and vericiguat 1.25 mg, 2.5 mg, 5.0 mg and 10.0 mg
groups, respectively (Figure 1A). Dose-dependent reductions in
hsCRP were observed; the analysis indicated a significantly greater
reduction in hsCRP with the vericiguat target dose of 10.0 mg
relative to placebo (−31.9% vs. 0.2%; P = 0.035) and a significant
linear trend in the reduction of hsCRP from baseline to end
of treatment from placebo up to the highest vericiguat dose of
10.0 mg (P = 0.039) (Table 3).
After 12 weeks of treatment, baseline-adjusted mean percent-
age changes from baseline in SUA were 5.0% (95% CI −0.1 to
10.4), −1.3% (95% CI −6.1 to 3.7), −1.1% (95% CI −5.8 to 3.8),
−3.5% (95% CI −8.3 to 1.6) and −5.3% (95% CI −9.8 to −0.6) in
the placebo, and vericiguat 1.25 mg, 2.5 mg, 5.0 mg and 10.0 mg
groups, respectively (Figure 1B). Significant reductions from base-
line in SUA were observed in the vericiguat 5.0 mg and 10 mg
groups relative to placebo [−3.5% vs. 5.0% (P = 0.02) and −5.3% vs.
5.0% (P = 0.004), respectively] and a significant linear trend in the
reduction of SUA from baseline to end of treatment from placebo
up to the highest vericiguat dose of 10.0 mg (P = 0.004) was appar-
ent (Table 3), indicating a dose-dependent effect.
Additional consideration of clinical covariates in the analysis did
not lead to noteworthy changes in the treatment effects (e.g. effect
ratios of 0.66 vs. 0.68 for hsCRP and 0.90 vs. 0.90 for SUA in
comparisons of 10.0 mg vericiguat and placebo in the model with
and without clinical covariates).
© 2020 Bayer AG Pharmaceuticals. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 2 Baseline characteristics by serum uric acid subgroup







N = 345 (33.6%) (46.1%) (20.3%)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Age, years, median (IQR) 68.0 (59.0–77.0) 71.0 (62.0–79.0) 67.0 (59.0–75.0) 63.0 (54.0–73.0) 0.001
BMI, kg/m2, median (IQR) 27.7 (24.3–31.5) 26.8 (23.2–30.2) 27.6 (24.8–31.4) 29.1 (26.2–33.6) 0.004
Female sex, n 76 (22.0%) 29 (25.0%) 32 (20.1%) 15 (21.4%) 0.637
Non-White race, n 76 (22.0%) 24 (20.7%) 32 (20.1%) 20 (28.6%) 0.344
NYHA class III/IV, n 152 (44.1%) 52 (44.8%) 67 (42.1%) 33 (47.1%) 0.761
Atrial fibrillation, n 167 (48.4%) 56 (48.3%) 78 (49.1%) 33 (47.1%) 0.970
Arterial hypertension, n 268 (77.7%) 89 (76.7%) 124 (78.0%) 55 (78.6%) 0.956
Coronary artery disease, n 174 (50.4%) 57 (49.1%) 81 (50.9%) 36 (51.4%) 0.950
Chronic kidney disease, n 128 (37.1%) 49 (42.2%) 52 (32.7%) 27 (38.6%) 0.267
Diabetes mellitus, n 168 (48.7%) 55 (47.4%) 80 (50.3%) 33 (47.1%) 0.874
DBP, mmHg, median (IQR) 75.0 (69.7–81.3) 74.8 (69.7–79.2) 75.3 (69.0–81.5) 76.3 (70.2–83.2) 0.480
SBP, mmHg, median (IQR) 121.3 (115.0–133.7) 125.3 (116.7–140.7) 120.7 (115.0–131.7) 119.3 (113.9–127.8) 0.010
Heart rate, b.p.m., median (IQR) 70.7 (62.3–81.0) 70.5 (61.7–76.8) 70.0 (62.5–81.0) 74.5 (64.7–85.3) 0.144
LVEF, %, median (IQR) 29.0 (23.2–35.8) 30.2 (25.6–37.6) 29.6 (23.0–36.0) 25.8 (21.8–33.1) 0.005
Serum sodium, mmol/L, median (IQR) 139.0 (137.0–141.0) 140.0 (138.0–141.0) 139.0 (136.0–140.5) 138.0 (136.0–140.0) 0.006
Serum creatinine, mg/dL, median (IQR) 1.2 (1.0–1.4) 1.1 (0.9–1.4) 1.2 (1.0–1.4) 1.4 (1.1–1.7) <0.001
eGFR, mL/min/1.73 m2, median (IQR) 56.3 (44.9–72.7) 60.2 (45.8–80.8) 59.2 (48.2–70.9) 47.2 (38.2–59.1) <0.001
BMI, body mass index; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; IQR, interquartile range; LVEF, left ventricular ejection fraction; NYHA, New
York Heart Association; SBP, systolic blood pressure; SUA, serum uric acid.
aP-values are based on Fisher’s exact tests for sex, race, NYHA class, atrial fibrillation, arterial hypertension, coronary artery disease, chronic kidney disease and diabetes
mellitus, and on Kruskal–Wallis tests for other baseline characteristics.









































































































































































*Two-sided P-value for difference with placebo arm
A B
Figure 1 Baseline-adjusted mean changes (%) in (A) high-sensitivity C-reactive protein (hsCRP) and (B) serum uric acid (SUA) from baseline
to end of treatment. CI, confidence interval; geom.mean, geometric mean. *Statistical significance relative to placebo.
© 2020 Bayer AG Pharmaceuticals. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.

















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































.. Estimated probability of achieving
biomarker thresholds at end
of treatment
The estimated probability for an end-of-treatment (week 12)
hsCRP value of ≤3.0 mg/L and SUA value of <7.0 mg/dL was
higher in all vericiguat treatment groups compared with placebo
(Figure 2). The estimated probability for an end-of-treatment
hsCRP value of ≤3.0 mg/L and SUA value of <7.0 mg/dL varied by
treatment and baseline biomarker level. The estimated probability
differences between all vericiguat treatment groups and placebo
for an end-of-treatment hsCRP value of ≤3.0 mg/L were com-
parable across baseline hsCRP values (Figure 2A). The estimated
probability increase (shift on y-axis) from placebo to vericiguat for
an end-of-treatment hsCRP value of ≤3.0 mg/L ranged from 8.3 to
14.6 percentage points in patients with a baseline hsCRP value of
4 mg/L (left dashed vertical line) and from 6.5 to 12.1 percentage
points in patients with a baseline hsCRP value of 10 mg/L (right
dashed vertical line) in the vericiguat 1.25 mg and 10.0 mg groups,
respectively.
The SUA model indicated that the estimated probability dif-
ference between all vericiguat treatment groups and placebo for
an end-of-treatment SUA value of <7.0 mg/dL was decreased in
patients with higher baseline SUA levels (Figure 2B). The esti-
mated probability increase from placebo to vericiguat for an
end-of-treatment SUA value of <7.0 mg/L ranged from 9.1 to
16.5 percentage points in patients with a baseline SUA value of
8.0 mg/dL and from 1.9 to 4.0 percentage points in patients with a
baseline SUA value of 11.0 mg/dL across the vericiguat treatment
groups.
The distributions of the hsCRP and SUA subgroups in the
placebo and 2.5–10.0 mg vericiguat treatment arms at baseline and
end of treatment are shown in Figure 2C and 2D. At baseline, 11, 22
and 33 patients in the 10.0 mg vericiguat treatment arm had hsCRP
values of <1.0 mg/L, 1.0–3.0 mg/L and >3.0 mg/L, respectively
(Figure 2C). Following 12 weeks of treatment with vericiguat, 20, 19
and 27 patients had hsCRP values of <1.0 mg/L, 1.0–3.0 mg/L and
>3.0 mg/L, respectively. Changes in the distribution of the hsCRP
subgroups were also observed in the placebo treatment group,
with fewer patients having an hsCRP value of <1.0 mg/L at week 12
than at baseline. These changes reflect a near doubling of patients
(from 11 to 20) with hsCRP values of <1.0 mg/L by week 12 in the
10.0 mg vericiguat treatment group.
At baseline, 24, 32 and 16 patients in the 10.0 mg vericiguat
treatment arm had SUA values of <7.0 mg/dL, 7.0–10.0 mg/dL
and >10.0 mg/dL, respectively (Figure 2D). At the end of vericiguat
treatment, 29, 30 and 13 patients had SUA values of <7.0 mg/dL,
7.0–10.0 mg/dL and >10.0 mg/dL, respectively. The distribution
of SUA subgroups in the placebo treatment arm was largely
unchanged throughout the study.
Association of biomarker changes from
baseline with clinical outcomes
The proportion of clinical outcome events (cardiovascular death,
cardiovascular hospitalization and emergency presentation caused
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Figure 2 Estimated probabilities for (A) high-sensitivity C-reactive protein (hsCRP) and (B) serum uric acid (SUA) reduction to below risk
level and (C, D) subgroup sizes per treatment arm at baseline and end of treatment (EoT). In (B), 1.25 mg and 2.5 mg vericiguat trend lines
overlap SUA data. Numbers within the bar charts represent the numbers of patients with specified (C) hsCRP or (D) SUA values at baseline
or EoT. The total numbers of patients per treatment arm for placebo and vericiguat 10.0 mg were 65 and 66, respectively, for hsCRP data, and
67 and 72, respectively, for SUA data.
by worsening chronic HF) was numerically smaller in patients with
decreases in hsCRP and SUA than in those with increases from
baseline (Table 4). Clinical outcome events occurred in 14.0% of
patients who had a decrease in hsCRP compared with 21.8%
who had an increase in hsCRP, relative to baseline, at the end of
treatment (P = 0.08). Similarly, clinical outcome events occurred










. 19.9% who had an increase in SUA, relative to baseline, at the end
of treatment (P = 0.26).
Other exploratory biomarkers
Geometric means at baseline and summary statistics of per-
centage changes from baseline in other exploratory biomarkers
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Table 4 Association of changes in high-sensitivity C-reactive protein and serum uric acid with clinical outcomes
Direction of biomarker change from
baseline to end of treatment
n Patients with
an event, n
Event proportion, % Odds ratio 95% CI P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
hsCRP
Increase 142 31 21.8% 0.58 0.31–1.08 0.08
Decrease 186 26 14.0%
SUA
Increase 176 35 19.9% 0.70 0.38–1.27 0.26
Decrease 169 25 14.8%
CI, confidence interval; hsCRP, high-sensitivity C-reactive protein; SUA, serum uric acid.
(bAP, cGMP, CTX, Gal-3, GDF-15, hsTnT, OPN, PIIINP, sST2 and
TIMP-4) are presented in supplementary material online Table S2.
There was no effect of treatment with vericiguat compared with
placebo on these biomarkers at week 12 (P-value of linear trend
test >0.05).
Discussion
Vericiguat treatment for 12 weeks was associated with a decrease
in hsCRP (significant in the vericiguat 10.0 mg group and a sig-
nificant dose-dependent trend) and SUA concentrations (signifi-
cant in the vericiguat 5.0 mg and 10.0 mg groups and a significant
dose-dependent trend) from baseline in patients with HFrEF. Sta-
tistically significant dose-dependent reductions in hsCRP and SUA
were observed in vericiguat-treated patients with HFrEF when data
were adjusted for baseline levels and clinical covariates.
Vericiguat treatment was also associated with a higher probabil-
ity of an hsCRP value of ≤3.0 mg/L at the end of the study than
placebo. The distribution of hsCRP subgroups in the 10.0 mg veri-
ciguat treatment arm revealed that the increase in patients with an
end-of-treatment hsCRP value of <1.0 mg/L corresponded with
fewer patients having an hsCRP value of ≥1.0 mg/L at week 12.
These novel results point to a potential anti-inflammatory effect
of sGC stimulation in patients with HFrEF after a recent worsen-
ing HF event who are post-hospitalization for HF or have required
outpatient treatment with i.v. diuretics.
The mechanism underlying the lowering of hsCRP by vericiguat
in patients with HFrEF is not directly addressed by these data. The
anti-inflammatory capacity of sGC stimulation has been shown
in a murine model of interleukin-1𝛽-induced leucocyte rolling
and adhesion, in which sGC stimulation with BAY 41–2272 (a
predecessor to the sGC activator) down-regulated P-selectin
expression and inhibited leucocyte recruitment.18 However,
studies using tumour necrosis factor inhibitors demonstrated no
improvement in HF-related outcomes.4 Similarly, although statin
treatment in the CORONA study was associated with a reduction
in CRP, the study did not meet its primary endpoint.4 It remains
to be determined whether hsCRP is a true prognostic biomarker
in relation to clinical outcomes.
Systemic inflammation in HF has previously been postu-
lated to result from an impaired intestinal mucosal barrier






























































.. ventricular (RV) HF. The intestinal damage leads to translocation of
lipopolysaccharides from the intestinal lumen into the circulation,
and endotoxaemia subsequently causes production of proinflam-
matory cytokines.19–23 Thus, a decrease in systemic inflammatory
markers could be hypothesized to reflect decreased peripheral
venous congestion as a potential consequence of improved RV
function and decreased right heart filling pressures. Reduced con-
gestion may also result in less hepatic congestion,24 which may, in
turn, result in lower levels of inflammation and oxidative stress.25
However, observed correlations between changes in hsCRP and
SUA and changes in echocardiographic parameters following
12 weeks of treatment were only very small and not supportive
of an imaging correlate reflecting lower RV filling pressures as an
underlying mechanism (data not shown). In patients who experi-
enced a decrease from baseline in hsCRP or SUA at week 12, the
relative odds of a clinical outcome were non-significantly reduced
compared with patients who had an increase from baseline in
hsCRP or SUA at end of treatment. The collection of biomarkers
from the Phase 3 vericiguat study VICTORIA (NCT02861534)
in patients with HFrEF will provide an opportunity to assess
clinical laboratory markers of haemodynamic right heart unloading
in parallel with echocardiography in an imaging ancillary study
as potential determinants of reduced systemic inflammation in
response to treatment with vericiguat.13 In addition, the longer
duration and increased number of clinical events in the VICTORIA
study will enable a more robust assessment of the associations
between inflammatory biomarkers and clinical outcomes.
Treatment with vericiguat in patients with HFrEF was associated
with a higher likelihood of SUA levels falling below the threshold
of hyperuricaemia (SUA ≥7.0 mg/dL) at the end of the study. The
magnitude of SUA reduction observed with vericiguat treatment in
this analysis is comparable with that achieved by sacubitril/valsartan
treatment in the PARADIGM-HF study.10 Hyperuricaemic lev-
els are associated with increased risk for cardiovascular death,
hospitalization for HF and all-cause mortality.26–28 The observed
reduction in uric acid levels following treatment with vericiguat
may also represent a potential protective mechanism to prevent
the deterioration of kidney function in HF and ameliorate car-
diorenal syndrome. Although they are not strongly correlated with
changes in eGFR (Spearman correlation −0.363 (95% CI −0.452 to
−0.267) (supplementary material online Table S3), the reductions
from baseline in SUA reported here (geometric mean: <0.5 mg/dL)
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are smaller than those reported in two dedicated SUA-lowering
trials in patients with HF (reductions of 2 mg/dL and 4.2 mg/dL),
which found no improvements in survival, hospitalization for HF or
LVEF.29,30 Thus, although effectively reducing SUA, the inconsistent
clinical efficacy of xanthine oxidase inhibitors in these studies called
into question the promise of SUA reduction to improve clinical
outcomes. This contrasts with the broad evidence base in support
of the pathophysiological relevance of an increase in SUA as a risk
factor for adverse outcomes in both HF and chronic kidney disease.
The SUA-reducing effect of vericiguat may support the hypothesis
that mechanisms other than the inhibition of SUA generation via
xanthine oxidase may have promise for tackling this risk factor.
The analysis of baseline characteristics by biomarker subgroup
revealed that the baseline demographic characteristics of younger
age and a higher body mass index were associated with higher
hsCRP and SUA values. Higher SUA but not higher hsCRP were
found at baseline in patients with worse renal function, more
severely reduced LVEF and lower serum sodium. With the excep-
tion of serum sodium, these findings are consistent with those
reported for SUA in the PARADIGM-HF study10 and suggest that
the clinical phenotype associated with higher hsCRP and SUA is
consistent with more advanced HF.
There was no effect of treatment with vericiguat compared with
placebo on other exploratory biomarkers associated with HF (bAP,
cGMP, CTX, Gal-3, GDF-15, hsTnT, OPN, PIIINP, sST2, TIMP-4) at
week 12; these results are consistent with those reported in the
full analysis set.14
One limitation of this analysis is that the mechanisms behind
the effects of vericiguat on hsCRP and SUA are unknown and
further studies are warranted to validate the prognostic value of
reducing SUA as a treatment target in therapeutic approaches in
HFrEF. Given the exploratory post hoc nature of the analysis,
these results should be considered as hypothesis-generating. It
should also be considered that elevated hsCRP levels at baseline
may reflect the presence of aetiologies other than HF, such as
metabolic conditions including insulin resistance.7 The analysis
of SUA changes from baseline to week 12 did not take into
consideration the concomitant use of SUA-altering therapies such
as diuretics. Additionally, this study was not powered for outcomes
and the reported associations between biomarkers and adverse
clinical outcomes should be interpreted with caution.
In conclusion, dose-dependent decreases in hsCRP and SUA
concentrations from baseline in patients with HFrEF were
observed following 12 weeks of treatment with vericiguat.
Whether the reductions in hsCRP and SUA with vericiguat
are sustained with longer periods of treatment and are associated
with improved clinical outcomes remains to be demonstrated in
the Phase 3 VICTORIA study (NCT02861534).13
Supplementary Information
Additional supporting information may be found online in the
Supporting Information section at the end of the article.
Table S1. Baseline characteristics of patients in the full analysis set



















































































.. Table S2. Baseline levels and changes from baseline to end of
treatment of additional biomarkers (per-protocol population).
Table S3. Correlation analysis of changes in estimated glomerular
filtration rate and body mass index with changes in log-transformed
high-sensitivity C-reactive protein and serum uric acid levels from
baseline to end of treatment.
Figure S1. SOCRATES-REDUCED study design.
Figure S2. Patient disposition in the SOCRATES-REDUCED
study.
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